US OptionsDetailed Quotes

CERS241115C3000

Watchlist
  • 0.02
  • 0.000.00%
15min DelayClose Nov 15 15:55 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    我要向钱看
    我要向钱看
    Oct 31 01:51
    $Cerus (CERS.US)$ Financial Performance:
    Cerus Corporation reported Q3 product revenue of $46 million, achieving a 16% year-over-year growth. The nine-month period product revenue summed up to $129.5 million, indicating an 18% increase from the prior year.
    Notable improvements in product gross margins which reached 56.9% in Q3, a rise of 200 basis points from the prior year's same period, attributed primarily to reduced product and supply chain costs.
    Operating expenses in Q3 amounted to $31.8...
    Jaguar8
    Jaguar8
    Oct 30 15:00
    NEWS
    $Cerus (CERS.US)$
    Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods
    Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million
    我要向钱看
    我要向钱看
    Oct 24 21:42
    UPDATES
    $Cerus (CERS.US)$$Cerus (CERS.US)$ is scheduled to release its financial results post-market on October 30 ET.
    Earnings Preview
    Analysts estimate $Cerus (CERS.US)$ to post revenue of USD47.80M for 2024Q3, up 20.18% YOY;
    EPS is estimated to be USD-0.03, Net Loss Narrowed 18.8% YoY.
    The accounting standard used for the above data is US-GAAP.
    我要向钱看
    我要向钱看
    Oct 16 22:06
    $5 TP
    $Cerus (CERS.US)$ TD Cowen analyst Josh Jennings maintains $Cerus (CERS.US)$ with a buy rating, and maintains the target price at $5.
    Jaguar8
    Jaguar8
    Oct 16 15:01
    NEWS
    $Cerus (CERS.US)$
    Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
    Cerus (Nasdaq:CERS) has provided updates on its INTERCEPT red blood cell (RBC) programs in the U.S. and Europe. In the U.S., Cerus has secured a new $248 million contract with BARDA to support the program through FDA approval and commercialization. The company recently announced positive topline results for the ReCePI study, a pivotal U.S. Phase 3 clinical trial.
    In Europe, the CE ...
Read more